

ASX ANNOUNCEMENT

28 April 2026

Revised Appendix 4C Quarterly Cash Flow Report

Biome Australia Limited (ASX: BIO) advises that it has released a revised Appendix 4C Quarterly Cash Flow Report. The revision corrects a formatting error affecting two line items within the Cash Flows from Operating Activities section, specifically items 1.2(d) and 1.7. The Total Net Cash from/(used in) Operating Activities as originally reported is correct and remains unchanged. All other information contained in the original announcement remains consistent.

-ENDS-

Approved for release by the Biome Australia Limited Board of Directors.

Investor Relations

Lauren Dwyer - CFO

corporate@biomeaustralia.com

Media enquiries

media@activated.co



ASX ANNOUNCEMENT

28 April 2026

Quarterly Activities & Appendix 4C March 2026

- Consumer sell-through surpassed 1 million boxes of *Activated Probiotics* on a rolling 12-month basis during Q3 FY26, a Company first confirmed by independent pharmacy scan data
- *Biome* on track to deliver its 100 millionth dose through community pharmacy and the healthcare practitioner channel within FY26
- Based on independent pharmacy scan data, *Activated Probiotics* is currently reported as the fastest-growing probiotic brand in Australian community pharmacy over the rolling 12 months, with *Biome Daily* approaching the number one probiotic product (currently #2) in total pharmacy by both units and value
- Fullscript Canada national launch commenced in Q3, opening North America's largest practitioner distribution channel to *Activated Probiotics*
- Net increase in cash at bank for Q3 FY26, closing at \$3,387k
- The Company continues to expect FY26 to be profitable, subject to normal trading conditions
- Brand marketing investment approximately 6.5% of 'sales, advertising and marketing' cost centre FYTD, with full breakdown to be provided in all future reporting periods
- *BMB18* human clinical trial at La Trobe University due to commence in Q4, enrolling 240 participants
- *BMB18* patent application lodged, a key milestone in *Biome's* intellectual property strategy and long-term competitive positioning
- Substantive update on onshore Australian manufacturing, a cornerstone of Vision 27, anticipated within calendar year 2026



Microbiome health company *Biome Australia Limited* (ASX: BIO) ('*Biome*' or '*the company*') is pleased to provide its Appendix 4C and Activity Report for the quarter ended 31 March 2026.

Activated Probiotics continues to grow as the fastest-growing probiotic brand in Australian community pharmacy, built through professional healthcare recommendation.

The result is a clear demonstration that underlying consumer demand for *Activated Probiotics*, driven by practitioner recommendation and clinical credibility, continues to accelerate across all markets independently of seasonal wholesale and retail buying trends. The Company expects to report a net profit for the full year FY26.

Consumer Sell-Through & Market Position


Independent pharmacy scan data confirms *Biome Daily* is approaching the number one probiotic product in total Australian pharmacy by both units and value. Since launching *Activated Probiotics* in late 2019, *Biome* is on track to deliver its 100 millionth dose through community pharmacy and the healthcare practitioner channel within Q4 FY26, a scale of clinical impact achieved in under six years, built entirely through professional healthcare recommendation.

Biome Daily Kids is the fastest-growing product in the children's probiotic segment and *Biome Baby* is the fastest-growing baby probiotic in pharmacy. All *Activated Probiotics* SKUs are reported as being in growth, a position which, based on available scan data, is not commonly observed across other probiotic brands in the Australian market.

Q3 FY26 Highlights

Q3 FY26 delivered the consumer sell-through milestone of one million boxes of *Activated Probiotics* on a rolling 12-month basis, the fastest-growing probiotic brand position in Australian community pharmacy, and a net increase in cash at bank. Immune health is the fastest-growing segment within the *Activated Probiotics* range, and all SKUs are reported as being in growth.

The Fullscript Canada national launch commenced in Q3, opening North America's largest practitioner distribution channel to *Activated Probiotics*. The Company's largest-ever brand investment, a national out-of-home and digital campaign, launched late in the quarter and is currently running across major metro markets through to mid-May 2026.



Q4 FY26 Outlook

Looking forward, three factors are converging to support Q4 FY26.

First, an exceptional respiratory illness season. Health authorities have indicated that the 2026 respiratory season may involve higher-than-average activity, relative to recent years, following a 2025 season in which Australia recorded more than 427,000 laboratory-confirmed influenza notifications, around 21% more than 2024 and the highest annual total since influenza became nationally notifiable in 2001. The newly identified A(H3N2) subclade K variant drove a late 2025 surge and continues to circulate in 2026, with health authorities flagging the year as a high-burden season and NIP influenza vaccines available from April 2026. Immune health is already the fastest-growing segment within the Activated Probiotics range heading into the peak cold and flu period.

Second, *Biome's* largest-ever brand investment. The Company's national out-of-home and digital campaign is currently running across major metro markets through to mid-May 2026, timed precisely to capture this demand.

Third, the Fullscript Canada national launch (detailed under International Markets below), which opened North America's largest practitioner distribution channel to Activated Probiotics during Q3.



For *Biome*, this convergence is not new. *The Company* built its business through COVID and the post-pandemic respiratory resurgence of 2022 and 2023. Historically, periods of elevated respiratory burden have been associated with increased practitioner engagement in immune health support products through the practitioner channel. The 2026 season presents the same dynamic with a materially stronger brand and a much larger distribution footprint. The

Company continues to expect FY26 to be profitable, subject to normal trading conditions.

BMB18: Proprietary Strain & Patent

The *BMB18* human clinical trial at La Trobe University is due to commence in Q4, being conducted as a randomised, double-blind, placebo-controlled study enrolling 240 participants. *BMB18* is a proprietary probiotic strain identified by Founder Blair Vega Norfolk and the Biome science team, identified and developed by the Company as part of its internal research program.

Biome has lodged a patent application for *BMB18*, a significant milestone in the Company's intellectual property strategy. A next generation probiotic strain, the subject of a patent application and currently undergoing clinical evaluation, is expected to further differentiate the *Activated Probiotics range relative to other products* on the market. *The Company* will provide a further update on this Vision 27 milestone in due course.

International Markets

International distribution across New Zealand, Canada, Ireland and the United Kingdom continued to develop through Q3. The Fullscript Canada national launch commenced in Q3, with all products approved and territory managers active across three provinces. Green Cross Health in New Zealand and Uniphar in Ireland are both delivering results in line with expectations. International revenue contribution continues to develop and is expected over time to provide significant diversification on the domestic sales base.

Biome Australia's Managing Director and Founder Blair Vega Norfolk said:

"Q3 has been a defining quarter for Biome. We surpassed one million Biome boxes of Activated Probiotics sold through on a rolling 12-month basis, a Company first, and we enter Q4 as the fastest-growing probiotic brand in Australian pharmacy, approaching number one position."

"With a more active respiratory season beginning to emerge, our largest-ever brand campaign now in market, and the Fullscript Canada launch now underway, the Company is well positioned heading into Q4."

"We have built this business through challenging economic conditions and continued to manage significant growth throughout. That reflects the trust practitioners place in the evidence, and the confidence patients place in their practitioners and our products, a dynamic that has proven resilient across economic cycles."




Quarterly Financial Update

From Q3 FY26, *the Company* has transitioned to reporting operational metrics as its primary quarterly performance indicators, with comprehensive financial results disclosed at the half-year and full-year intervals. This approach more accurately reflects the underlying health of the business and is consistent with *Biome's* evolution as a profitable, cash-generative enterprise. On a full year basis, FY26 EBITDA is on track to represent a transformational step-change relative to FY25, reflecting the operating leverage now evident as the business scales.

The Company wishes to draw attention to an important change in how it will present its expense profile going forward. Historically, *Biome's* financial disclosures have applied an inconsistent mix of expense-by-nature and expense-by-function formats across ASX releases (interim and annual financial statements), making it difficult for the market to clearly assess the Company's true operating cost base. This will be standardised in all future reporting periods.

Taking Sales & Marketing as an illustrative example, the previously disclosed expenditure aggregates three materially distinct cost categories: employee costs; distribution and pharmacy channel costs, including co-operation contributions to banner group partners; and direct brand marketing investment, comprising media, out-of-home, digital and creative expenditure. When disaggregated, direct brand marketing investment represents approximately 6.5% of this cost centre (FY26 YTD), with the balance comprising people and distribution costs that are structural to *Biome's* practitioner-led go-to-market model. This breakdown demonstrates that *Biome's* 40%+ revenue growth (H1 FY26 vs PCP) is being driven by clinical evidence and practitioner advocacy, not marketing expenditure - and that the model scales efficiently as the business grows.

The Company advises that a substantive update on onshore Australian manufacturing, a cornerstone of Vision 27, is anticipated within calendar year 2026. The Board regards this as one of the most consequential operational milestones on *Biome's* near-term horizon, which is expected to deliver a structural improvement in cost of goods sold, the benefits of which will compound as revenue scale increases and fixed manufacturing costs are progressively absorbed across a larger volume base. For *Biome*, onshoring will eliminate the concentration risk inherent in offshore manufacturing, reduce exposure to currency fluctuation, international freight volatility and supply chain disruption, while providing the operational agility to scale production in line with the continuing growth trajectory.



The amount paid to Directors of the Company during the quarter was \$178,937 in fees, salaries and superannuation payments, as follows:

- Executive Director \$120,000
- Non-Executive Directors \$58,937

–ENDS–

Approved for release by the Biome Australia board of directors.

Investor Hub

Biome has launched a new interactive investor hub. To view a video presentation of this announcement, ask questions or sign up for future company updates, please visit the investor hub at <https://investorhub.biomeaustralia.com/>.

About Biome Australia Limited

Biome Australia develops, licences, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. *Biome* aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, *Biome* distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, *Biome* produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: *Activated Probiotics*®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, *Activated Probiotics* and *Activated Therapeutics* help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, *Biome* is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations


Lauren Dwyer
corporate@biomeaustralia.com
(03) 9017 5800



Biome Australia Limited
192–194 Johnston Street
Collingwood VIC 3066

+61 3 9017 5800
support@activated.co
biomeaustralia.com

ASX:BIO
ACN 627 364 014



Forward Looking Statements

This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (Forward Looking Statements). Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Patent applications are subject to examination processes and grant is not guaranteed. Clinical trial results cannot be predicted and may not support commercial development. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

BIOME AUSTRALIA LIMITED (BIO)

ABN

51 627 364 014

Quarter ended ("current quarter")

31st March 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	4,889	18,236
1.2 Payments for		
(a) research and development	(82)	(312)
(b) inventory and fulfilment	(3,366)	(9,638)
(c) sales, advertising and marketing	(704)	(1,819)
(d) other operating receipts (costs)	21	(51)
(e) staff costs	(1,659)	(5,037)
(f) administration and corporate costs	(268)	(958)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(62)	(144)
1.6 Income taxes and FBT paid	(4)	(14)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
1.7	Government grants and tax incentives	-	657
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	(1,235)	920

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(38)	(91)
	(d) investments	-	-
	(e) intellectual property	(47)	(156)
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:	-	-
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(85)	(247)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	246	354
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	525	525
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Payments for lease liabilities	(70)	(128)
3.6	Proceeds from/ (repayment of) borrowings	650	(783)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if relevant)	-	-
3.10	Net cash from / (used in) financing activities	1,351	(32)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	3,356	2,746
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,235)	920
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(85)	(247)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,351	(32)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	3,387	3,387

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	3,387	3,356
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,387	3,356



6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	179
6.2	Aggregate amount of payments to related parties and their associates included in item 2	Nil
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		
The amount paid to Directors of the Company during the quarter was \$178,937 in fees, salaries and superannuation payments, as follows:		
• Executive Director \$120,000 • Non-Executive Directors \$58,937		
7.	Financing facilities <i>Note: the term “facility” includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000 Amount drawn at quarter end \$A'000
7.1	Loan facilities	5,0002,123
7.2	Credit standby arrangements	Niln/a
7.3	Other (please specify)	Niln/a
7.4	Total financing facilities	5,0002,123
7.5	Unused financing facilities available at quarter end	2,877
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

Biome Australia Trading Pty Ltd ("Biome Trading") a wholly owned subsidiary of The Company has entered into a \$5.0m secured debt facility ("Facility") with NAB for working capital purposes to fund future growth, comprising a \$3.5m NAB Invoice Finance Facility and a \$1.5m NAB Trade Finance Facility.

\$3.5m NAB Invoice Finance Facility

This facility will provide invoice funding for Biome's Australian accounts receivables. The current interest rate of the facility is 7.75%. The facility carries an application fee of \$12,250 plus a monthly facility fee of \$1,700. This is an ongoing facility with no set expiry date.

\$1.5m NAB Trade Refinance Facility

The current interest rate of the facility is 7.53% p.a. The facility carries an application fee of \$5,250 plus a facility fee of 1.3% p.a. This facility was set to expire on 27 February 2026 and was extended by a year, to 27 February 2027. The facility is secured by a General Security Agreement over the whole of Biome Trading's assets, a First ranking priority charge over the whole of Biome Trading's receivables (debtor) book and a Deed of Guarantee and Indemnity from the Company, supported by a General Security Agreement over the whole of the assets of the Company.

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,235)
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,387
8.3	Unused finance facilities available at quarter end (item 7.5)	2,877
8.4	Total available funding (item 8.2 + item 8.3)	6,264
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	5.1
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: n/a

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: n/a

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: n/a

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:28 April 2026.....

Authorised by:Authorised by the Board.....
(Name of body or officer authorising release – see note 4)



Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

